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Abstract: Protein kinase CK2, also known as casein kinase-2, is involved in a broad range 
of physiological events including cell growth, proliferation and suppression of apoptosis 
which  are  related  to  human  cancers.  A  series  of  compounds  were  identified  as  CK2 
inhibitors and their inhibitory activities varied depending on their structures. In order to 
explore the structure-activity correlation of CX-4945 derivatives as inhibitors of CK2, in 
the present study, a set of ligand- and receptor-based 3D-QSAR models were developed 
employing Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular 
Similarity Index Analysis (CoMSIA). The optimum CoMFA (Rcv
2 = 0.618, Rpred
2 = 0.892) 
and  CoMSIA  (Rcv
2  =  0.681,  Rpred
2  =  0.843)  models  exhibited  reasonable  statistical 
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characteristics  for  CX-4945  derivatives.  The  results  indicated  that  electrostatic  effects 
contributed the most to both CoMFA and CoMSIA models. The combination of docking 
analysis  and  molecular  dynamics  (MD)  simulation  showed  that  Leu45,  Lys68,  Glu81, 
Val116,  Asp175  and  Trp176  of  CK2  which  formed  several  direct  or  water-bridged  
H-bonds with CX-4945 are crucial for CX-4945 derivatives recognition to CK2. These 
results can offer useful theoretical references for designing more potent CK2 inhibitors. 
Keywords: CK2 inhibitors; 3D-QSAR; molecular docking; molecular dynamics 
 
1. Introduction 
The  casein  kinase-2  (CK2)  is  a  pleiotropic,  highly  conserved  serine/threonine  protein  kinase 
ubiquitously expressed in both the cytoplasm and the nucleus of eukaryotic cells [1–3]. The protein is 
comprised  of  tetramer  which  contains  two  catalytic  subunits,  α  and/or  α′  (37–44  kD),  and  two 
regulatory  β-subunits  (24–28  kD)  in  various  combinations.  CK2  possesses  constitutive  catalytic 
activity with the ability to phosphorylate more than 300 physiological substrates and does not require 
phosphorylation by other kinases for activation [2]. Naturally, these features make CK2 appear at 
extremely diverse points of cell signaling pathways, including PI3K/Akt and Wnt signaling cascades, 
NF-κB transcription, and the DNA damage response (reviewed in refs. [1] and [4]), and be involved in 
a number of cellular events contributing to the development of various disorders, particularly cancer. 
These data, in conjunction with the observation that many viruses exploit CK2 as phosphorylating 
agent of proteins essential to their life cycle [2], have made CK2 an attractive yet underexploited new 
therapeutic target for the treatment of cancer [5]. 
To study the function of protein kinase CK2, an effective approach is the use of small molecule 
inhibitors.  Thus,  intensive  efforts  have  been  devoted  toward  the  development  of  new  potent  and 
selective CK2 inhibitors which provides a powerful tool to extend our knowledge about CK2 function 
as well as to regulate its activity both in case of health and disease. Most protein kinase inhibitors of 
practical interest, including many of those that have entered clinical practice, are competitive with 
respect to the phosphodonor substrate ATP, which indicates that the binding modes of inhibitors and 
ATP are mutually exclusive [6]. Compared with most of other protein kinases, CK2 has a smaller ATP 
binding site as a result of the presence of unique bulky residues [7], allowing for the design of highly 
selective  low  molecular  weight  ATP-competitive  inhibitors  [8,9].  Up  to  now,  many  classes  of  
ATP-competitive  CK2  inhibitors  such  as  hydroxyantraquinones,  hydroxylcoumarines,  flavonoids, 
halogenate benzimidazoles and indoloquinazoline [6] have already been discovered, some of which 
achieved  the  promising  inhibition  potency  in  enzyme  assays.  Especially,  some  compounds  like  
3,8-dibromo-7-hydroxy-4-methylchromen-2-one (DBC) [10] outstand themselves by their advantage 
that their coumarinic scaffold does not act as a DNA intercalator, a property that reduces the side 
effects  with  respect  to  the  emodin  related  inhibitors  having  antraquinone  scaffolds.  Despite  these 
encouraging advances, development of potent and selective CK2 inhibitors still remains a difficult task 
for scientists [11,12]. In order to facilitate the drug discovery process, in silico screening and library 
design as a productive and cost-effective technology in design of novel lead compounds should be Int. J. Mol. Sci. 2011, 12 
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used  in  combination  with  experimental  practices  [13].  Presently,  three-dimensional  quantitative 
structure–activity  relationship  (3D-QSAR)  method,  including  comparative  molecular  field  analysis 
(CoMFA) [14] and comparative molecular similarity analysis (CoMSIA) [15] which have been widely 
used  in  drug  design,  is  a  useful  tool  to  rationalize  the  molecular  structural  variations  with  their 
inhibitory activities. Together with the visualized contour maps of 3D-QSAR model, docking study 
and molecular dynamics (MD) simulation [12], it could provide deep insight into understanding the 
QSAR by taking into account the structural properties of the active site of protein, and thus could more 
effectively direct the design of new potential inhibitors. 
Recent  studies  suggested  that,  due  to  its  diverse  pharmacological  properties  and  therapeutic 
applications,  CX-4945  has  been  regarded  as  the  most  promising  candidates  against  CK2  [15].  
To improve the medicinal properties and eliminate or reduce untoward effects of these compounds, 
several  groups  have  performed  a  series  of  optimization  procedures  on  them,  resulting  in  some 
compounds with good activity both in the enzymatic and cell culture assays [15,16]. CX-4945, as the 
only one orally administered highly selective and potent CK2 inhibitor, has entered phase I clinical 
trials [16]. Thus development of new potent and selective CK2 inhibitors is a task of great importance. 
In this study, low energy conformation with ligand-based and receptor-based alignments was employed 
to build 3D-QSAR models for CX-4945 derivates. The predictive abilities of the obtained models were 
validated statistically with a representative test set of compounds. In addition, docking analysis and 
molecular dynamics (MD) simulation were also performed to elucidate the probable binding modes of 
these inhibitors. The combined in silico approaches have generated several 3D-QSAR models to gain 
insight into the key structural factors affecting their inhibitory activity and thus aid in designing new 
potent CK2 inhibitors with fewer side effects.  
2. Materials and Methods 
2.1. Data Sets 
By removing compounds with unspecified inhibitory activity or undefined stereochemistry, a total 
of 50 CX-4945 analogues were taken from the literature [17]. All in vitro biological activities (IC50) 
were converted into the corresponding pIC50 (−lg IC50) values, which were used as dependent variables 
in the QSAR study. The total data set of analogues was divided into training and test sets in a ratio of 
4:1. The structures and corresponding pIC50 values of the compounds in the training and test sets are 
given in Table 1. As a general rule, for a reliable 3D-QSAR model, the spread of activity should cover 
at least three log units, and there ideally should be a minimum of 15–20 compounds in the training  
set [18]. The activity range of CX-4945 derivatives is from 5.900 to 9.000 pIC50 units (see Table 1), 
covering four log activity distribution intervals, and there were 40 compounds in the training set. Int. J. Mol. Sci. 2011, 12 
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Table 1. The structures of the training and test set molecules of CX-4945 CK2 inhibitors. 
No.  Structure  IC50 (µM)  pIC50 
1 
 
0.08  7.097 
 
No.    R2  IC50 (µM)  pIC50 
2  –CO–NH–  –COOH  2.1  5.678 
3 
†  –CO–N((CH2)3OH)–  –COOH  1.5  5.824 
4  –(C–O(CH2)3OH)=N–  –COOH  0.99  6.004 
5  –(C–NH(CH2)3OH)=N–  –COOH  0.75  6.125 
 
No.  –NR3R4  R2  IC50 (µM)  pIC50 
6  –NH–(CH2)2OH  –COOH  1.26  5.900 
7 
†  –NH–(CH2)2NMe2  –COOH  0.102  6.991 
8  –Pyrrolidino  –COOH  1.780  5.750 
9  –NH–phenyl  –COOH  0.092  7.036 
10  –NMe–phenyl  –COOH  1.070  5.971 
11 
†  –NH–(2–Me–phenyl)  –COOH  0.970  6.013 
12  –NH–phenyl  –C-(1H-tetrazol-5-yl)  0.096  7.018 
13  –NH–(CH2)2Ph  –COOH  0.516  6.287 
14  –NH–(4–F–phenyl)  –COOH  0.219  6.660 
15  –NH–(3–F–phenyl)  –COOH  0.068  7.168 
16 
†  –NH–(4–Cl–phenyl)  –COOH  0.178  6.750 
17  –NH–(3–Cl–phenyl)  –COOH  0.032  7.495 
18  –NH–(3–MeO–phenyl)  –COOH  0.077  7.114 
19  –NH–(3–acetylenyl–phenyl)  –COOH  0.028  7.553 
20  –NH–(3–(PhO)–phenyl)  –COOH  0.395  6.403 
21 
†  –NH–(3–(CONHMe)–phenyl)  –COOH  0.129  6.889 
22  –NH–(3–Cl–phenyl)  –C-(1H-tetrazol-5-yl)  0.129  6.889 
23  –NH–(3–F–phenyl)  –C-(1H-tetrazol-5-yl)  0.075  7.125 
 
No.  A ring  IC50 (µM)  pIC50 
24 
 
0.092  7.036 Int. J. Mol. Sci. 2011, 12 
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Table 1. Cont. 
25 
 
0.006  8.222 
 
No.  R3  IC50 (µM)  pIC50 
26  –(CH2)2NMe  0.025  7.602 
27 
†  –cyclopentyl  0.027  7.569 
28  –OMe  0.008  8.097 
29  –cyclopropyl  0.016  7.796 
30  –(CH2)2O-i-Pr  0.011  7.959 
31  –(CH2)phenyl  0.009  8.046 
32 
†  –(CH2)2phenyl  0.003  8.523 
33  –(CH2)3phenyl  0.016  7.796 
34  –(3-MeO-phenyl)  0.004  8.398 
35  –(3-Cl,4-F-phenyl)  0.004  8.398 
36  –(3-F-phenyl)  0.005  8.301 
37 
†  –(2-Cl-phenyl)  0.008  8.097 
38  –(3-Cl-phenyl)  0.001  9.000 
39  –(4-Cl-phenyl)  0.007  8.155 
40  –(3-acetylenyl-phenyl)  0.003  8.523 
41  –(3-CN-phenyl)  0.004  8.398 
42  –(4-(PhO)-phenyl)  0.069  7.161 
43 
†  –(3-(PhO)-phenyl)  0.019  7.721 
44  –(3-(SO2NH2)-phenyl)  0.043  7.367 
 
No.  A1  A3  A4  R1  R2  R3  IC50 (µM)  pIC50 
45  –CH=  –N=  –CH=  –H  –C-(1H-tetrazol-3-yl)  –H  0.045  7.347 
46 
‡  –CH=  –N=  –CH=  –H  –CONH2  –H  0.417  6.380 
47  –CH=  –N=  –CH=  –Me  –COOH  –H  0.006  8.222 
48  –CH=  –N=  –CH=  –H  –H  –COOH  0.350  6.456 
49  –N=  –CH=  –N=  –H  –COOH  –H  0.220  6.658 
50 
†  –N=  –N=  –CH=  –H  –COOH  –H  0.007  8.155 
† Test set molecule; 
‡ Outlier. 
2.2. Conformational Sampling and Alignment 
Molecular  alignment  of  compounds  is  an  important  step  in  the  development  of  CoMFA  and 
CoMSIA models. To derive the best possible 3D-QSAR statistical model, two different alignment rules Int. J. Mol. Sci. 2011, 12 
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(ligand-based and receptor-based alignments) were adopted in this study. In the ligand-based alignment, 
the 3D structures of all compounds were constructed and subjected to full geometry optimization using 
the sketch molecule module of SYBYL 6.9 package (Tripos Associates, St. Louis, MO). Partial atomic 
charges were calculated by the Gasteiger-Huckel method, and energy minimization was performed by 
using the Tripos force field and the Powell conjugate gradient algorithm with a convergence criterion 
of 0.05 kcal/mol·Å. Then inhibitors were superimposed on the most potent molecule (compound 38) 
according to the common substructure depicted in bold (Figure 1(A)), and the resulting ligand-based 
alignment model is shown in Figure 1(B). In the receptor-based alignment, the protonation states of the 
titratable groups of CK2 were checked by using Whatif [19], the  model pKas for ligand titratable 
groups were calculated by SPARC [20]. Then computational docking was performed using Surflex 
module of SYBYL package. All inhibitors were aligned according to the bioactive conformations in 
the binding pocket of CK2α (PDB entry code: 3NGA) obtained from docking with Gasteiger Huckel 
charge (Figure 1(C)).  
Figure 1. (A) Compound 38 used as a template for alignment. The common substructure is 
shown in bold. Ligand- and receptor-based alignments of all the compounds are shown in 
panels (B) and (C), respectively. 
 
2.3. CoMFA and CoMSIA 3D-QSAR Models 
The  original  setup  for  CoMFA  and  CoMSIA  modeling  was  similar  to  our  earlier  work  [13].  
In summary, CoMFA was carried out using steric and electrostatic potential fields while CoMSIA was Int. J. Mol. Sci. 2011, 12 
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based  on  five  fields  (steric,  electrostatic,  hydrophobic,  H-bond  donors  and  acceptors).  All  the 
calculations were performed using Sybyl software. 
In the partial least-square (PLS) regression analyses, CoMFA and CoMSIA descriptors were used as 
independent variables and the pIC50 values were used as dependent variables to derive the 3D-QSAR 
models. The predictive values of the obtained models were evaluated using leave-one-out (LOO) cross 
validation method. The correlation coefficient R
2, F value and standard error of estimates (SEE) were 
calculated. The models were also evaluated for their ability to predict the activity of compounds in the 
test set. The predictive R
2 (denoted by Rpred
2) was calculated by Equation 1.  
2
pred 1 (PRESS SD) R = − −   (1) 
where SD is the sum of squared deviations between the biological activities of the test set and the 
mean activity of the training set molecules, and PRESS is the sum of squared deviation between the 
actual and predicted activities of the test set molecules. The optimum number of components (ONC) 
corresponding to the lowest PRESS value was used for deriving the final PLS regression models.  
2.4. Molecular Dynamics 
Molecular dynamics simulations were carried out using the Amber 10 package [21] by starting the 
docked structure. Ligand parameters and charges were determined with the antechamber module of 
Amber 10 based on the general atom force field (GAFF) [22] and the AM1-BCC charge scheme [23]. 
The standard AMBER force field for bioorganic systems (ff03) [24] was used to describe the protein 
parameters. All systems were solvated in a rectangular box of TIP3P water [25], keeping a minimum 
distance of 10 Å between the solute and each face of the box. The system was neutralized, and 0.15 M 
sodium chloride was added to the simulation box. To remove possible bad contacts, the complex was 
energy minimized by a multistep procedure including 500 steepest-descent steps followed by 9500 
conjugate-gradient steps. 
Then the solvent molecules in the minimized models were heated up to 300 K and equilibrated  
200 ps with the positional restraints on the protein heavy atoms. The MD simulations were performed 
in the NPT ensemble at constant pressure (1 atm) with isotropic position scaling and at 300 K. Finally, 
the production phase was run for 5 ns with a 2 fs time step. The long-range electrostatics was treated 
by using the particle-mesh-Ewald (PME) method [26] with default values. 
3. Results and Discussion 
Since the structural alignment of the compounds is crucial to develop a successful 3D-QSAR model, 
in  this  study,  two  rules  (both  ligand-  and  docking-based)  are  employed  to  align  each  class  of 
compounds  to  derive  the  reliable  CoMFA  and  CoMSIA  models.  The  results  obtained  from  both 
alignment methods using the same training set compounds are summarized in Table 2. The selected 
test set (representing 25% of the training set), which was not included in the model training process, 
was used to evaluate the predictive power of the CoMFA and CoMSIA models. There are several 
statistical  parameters,  i.e.,  the  cross-validated  correlation  coefficient  (rcv
2),  non-cross-validated 
correlation  coefficient  (rncv
2),  standard  error  of  estimate  (SEE)  and  F-statistic  values  (F)  that  are 
inherent in appraising a QSAR model for the compounds to be studied. Int. J. Mol. Sci. 2011, 12 
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For CoMSIA models, all possible combinations of fields were evaluated to determine which of the 
five fields are actually needed for the generation of a predictive model, because the five descriptor 
fields  are  not  totally  independent  of  each  other  and  such  dependencies  of  individual  fields  might 
decrease the statistical significance of the models. In the present work all 31 possible combinations of 
the descriptors were attempted to build the optimum models with highest Rcv
2 values and other proper 
statistical results. The resultant optimum models exhibited agreeable statistical results for this class of 
compounds (Table 2). 
Table 2. Summary of Comparative Molecular Field Analysis (CoMFA) and Comparative 
Molecular  Similarity  Index  Analysis  (CoMSIA)  results  of  ligand-  and  docking-based 
models about CX-4945 derivatives. 
Parameters  Ligand-based alignment  Docking-based alignment 
CoMFA  CoMSIA  CoMFA  CoMSIA 
Rcv
2  0.618  0.681  0.562  0.545 
ONC  3  3  4  5 
SEP  0.567  0.518  0.616  0.637 
Rncv
2  0.860  0.828  0.877  0.791 
SEE  0.343  0.380  0.326  0.187 
F value  71.892  56.197  62.523  173.161 
Rpred
2  0.892  0.843  0.556  0.580 
Field contribution 
Steric  0.423  0.180  0.668  0.151 
Electrostatic  0.567  0.820  0.332  0.246 
Hydrophobic  -  -  -  0.321 
Acceptor  -  -  -  0.282 
Rcv
2  =  Cross-validated  correlation  coefficient  using  leave-one-out  procedure;  
Rncv
2  =  Non-cross-validated  correlation  coefficient;  SEE  =  Standard  error  of  estimate;  
F  =  Ratio  of  Rncv
2  explained  to  unexplained  =  Rncv
2/(1  −  Rncv
2);  Rpred
2  =  Predicted  correlation 
coefficient for the test set of compounds; SEP = Standard error of prediction; ONC = Optimal 
number of principal components.  
3.1. Validation of the 3D QSAR Models 
CoMFA  model  validated  internally  yielded  Rcv
2  =  0.618  with  three  optimum  components  and  
Rcv
2 = 0.562 with four optimum components for the ligand- and docking-based alignment methods, 
respectively. Then the number of components identified in the LOO cross-validation process was used 
in the final non-cross-validated PLS run. As a consequence, the training set of 40 compounds led to 
Rncv
2 = 0.860, SEE = 0.343, F = 71.892, Rpred
2 = 0.892 and Rncv
2 = 0.877, SEE = 0.326, F = 62.523, 
Rpred
2 = 0.556 for ligand- and docking-based models, respectively. The electrostatic field makes more 
contribution  to  the  activity  (~56.7%)  in  ligand-based  CoMFA  model  while  less  (~33.2%)  in  the 
docking-based one. 
CoMSIA  modeling  gave  Rcv
2  =  0.681  at  three  PLS  components,  Rncv
2  =  0.828,  Rpred
2  =  0.843,  
SEE = 0.380 and SEP = 0.518 with steric of 18.0% and electrostatic of 82.0% field contributions for 
the  ligand-based  alignment,  while  yielded  Rcv
2  =  0.545  at  five  PLS  components,  Rncv
2  =  0.791,  Int. J. Mol. Sci. 2011, 12 
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Rpred
2 = 0.580, SEE = 0.187 and SEP = 0.637 with steric of 15.1%, electrostatic of 24.6%, hydrophobic 
of  32.1%  and  H-bond  acceptor  of  28.2%  field  contributions  for  the  docking-based  alignment, 
respectively. All these results suggested that ligand-based alignment of this class of compounds led to 
the  models  with  larger  Rcv
2,  Rncv
2,  Rpred
2  and  lower  SEE,  SEP  values  than  those  obtained  from  
receptor-based alignment. Therefore, the ligand-based 3D-QSAR models of this class of compounds 
were chosen as the optimal model in this work and utilized for further discussion. 
During  the  cross-validation  procedure,  compound  46  is  detected  as  an  outlier  (whose  residual 
between  the  experimental  and  predicted  values  is  more  than  1.5  log  unit)  for  both  CoMFA  and 
CoMSIA models. Some reasons may cause this appearance as an outlier. Compound 46 has a unique 
structure feature including an amide segment probably responsible for specific interactions which may 
make it an outlier. To test the predictive ability of the model, a test set of ten molecules excluded from 
the  model  derivation  was  employed.  The  predictive  correlation  coefficients  Rpred
2  of  ligand-based 
CoMFA and CoMSIA models were 0.892 and 0.843, respectively. The average absolute residuals of 
the predicted vs. corresponding experimental pIC50 values were 0.256 and 0.259, respectively. The plot 
of actual activity versus predicted pIC50 of the training set and test set was illustrated in Figure 2. The 
plots represent a uniform distribution around the regression line, indicating the satisfactory predictive 
capability and accuracy of the model. 
Figure 2. (A) Plot of the predicted pIC50 versus the experimental pIC50 values for CoMFA 
analysis.  (B)  Plot  of  predicted  activities  versus  experimental  activities  for  CoMSIA 
analysis. The solid lines are the regression lines for the fitted and predicted bioactivities of 
training and test compounds. 
 
3.2. 3D-QSAR Contour Maps 
CoMFA  and  CoMSIA  contour  maps  are  generated  by  interpolating  the  products  between  the  
3D-QSAR coefficients and their associated standard deviations to visualize the information of the 
derived  3D-QSAR  models.  The  maps  depict  regions  having  scaled  coefficients  greater  than  80% 
(favored) or less than 20% (disfavored). To aid in visualization, the most active compound is shown 
with the contour maps which indicate regions in 3D space around the molecules where changes in the 
particular physicochemical properties are able to explain the experimental binding differences. The Int. J. Mol. Sci. 2011, 12 
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combination of CoMFA and CoMSIA approaches enables one to check the convergence of the results, 
or to obtain conclusions that can complement each other [27,28]. In such a case, exploiting the results 
of both approaches leads to an optimal interpretation at the 3D level of the QSAR [28,29]. Thus, they 
not only rationalize the quantitative relationship between the molecular structures and their activity, 
but also provide valuable structural optimization clues for drug design. 
The CoMFA contour maps (Figure 3A,B) generated from the model derived by steric/electrostatic 
field  combination  are  the  same  as  the  CoMSIA  contour  maps  (Figure  4A,B)  obtained  by 
steric/electrostatic field combination, indicating the convergence of the results. For steric fields, the 
green and yellow contours describe regions of space around the molecules, in which green colored 
regions indicate areas where increased steric bulk links with enhanced activity, and yellow regions 
suggest areas where increased steric bulk is unfavorable to activity. Compound 38 was selected as a 
reference molecule to aid the visualization. As illustrated in Figures 3(A) and 4(A), a median green 
contour is found adjacent to the positions -19 and -20 of ring D, thus molecules which carry bulkier 
substituents such as chlorine at position-20 (compound 38) are more active than those compounds with 
less bulky substitutions like fluorine at the same position (compound 36). Thereby, an addition of 
bulky  groups  at  these  positions  around  the  green  contour  probably  improves  the  potency  of  the 
inhibitors. Another group of CoMFA and CoMSIA sterically disfavored yellow contours are present 
outside ring D, which strongly delimits the size of the side-chain around ring-D. For instance, the low 
potency  of  compounds  like  10,  11  and  33  is  probably  attributed  to  the  presence  of  too  bulky 
substituents at position-15, which conflicts with the yellow forbidden region. This suggests that the 
optimal  length  of  the  substituents  at  position-15  will  enhance  the  activity  of  these  compounds  
(32 and 38). Furthermore, the yellow contour around position-19 and -20 of ring D is farther than the 
green one, indicating too bulky groups at these positions are unfavorable.  
Figure 3. CoMFA StDev * Coeff contour plots. (A) Steric (green/yellow) contour map 
combined  with  compound  38.  Green  contours  indicate  regions  where  bulky  groups 
increase activity; yellow contours indicate regions where bulky groups decrease activity. 
(B) Electrostatic contour map (red/blue) in combination with compound 38. Red contours 
indicate regions where negative charges increase activity; blue contours indicate regions 
where positive charges increase activity. 
 Int. J. Mol. Sci. 2011, 12 
 
 
7014 
In the electrostatic field contour maps of CoMSIA and CoMFA, the red contours show favorable 
electronegative regions, and the blue contours show the regions where the electropositive charges are 
favored for enhancing the bioactivity. As shown in Figures 3B and 4B, a huge blue contour around ring 
C indicates the importance of electropositive substituent at this position to the inhibitory activity. For 
examples,  compound  17  with  a  –COOH  at  position-2  of  ring  C  exhibited  better  potency  than 
compound 22 which possesses a -C-(1H-tetrazol-5-yl) group at the same position. In addition, another 
electropositive  favorable  blue  contour  near  position-15  suggests  that  maybe  substituents  more 
positively charged (like the –NH– of compound 10) than –NMe– (of compound 09) in this region are 
good for increasing the activity. Therefore, reasonable structural modifications can be carried out to 
improve the activity and selectivity of CK2α inhibitors. Another red contour near position-12 of ring A 
indicates that electronegative groups at this region will enhance the activity. For examples, compound 50, 
having relatively electropositive group (=N– at position-12) is more active than compound 49 wherein 
=CH– group is attached. Compound 25 having relatively electronegative group ( ) is more active 
than compound 24 (with  group at the same location).  
Figure 4. CoMSIA StDev * Coeff contour plots. (A) Steric (green/yellow) contour map 
combined  with  compound  38.  Green  contours  indicate  regions  where  bulky  groups 
increase activity; yellow contours indicate regions where bulky groups decrease activity. 
(B) Electrostatic contour map (red/blue) in combination with compound 38. Red contours 
indicate regions where negative charges increase activity; blue contours indicate regions 
where positive charges increase activity. 
 
3.3. Docking Analysis and Comparison with 3D Contour Maps 
Besides the ligand-based 3D-QSAR studies, molecular docking for all 50 inhibitors was performed 
not only to understand the nature of interactions between these compounds and CK2α kinase but also 
to complement the 3D-QSAR analysis for the rational design of drugs. 
Before docking analysis, a redocking process of the cocrystallized ligand compound 38 (CX-4945) 
into  CK2α  receptor  (PDB  code:  3NGA)  was  carried  out  to  validate  the  docking  protocol  and 
parameters used. The top-ranked docked solution was found in one favorable cluster of docking poses Int. J. Mol. Sci. 2011, 12 
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with average root-mean-square deviation (RMSD) values ranging from 0.3 to 1.9 Å for the 10 top-ranked 
docking  poses,  suggesting  the  binding  mode  is  successfully  reproduced.  Additionally,  several  key 
residues including Lys68, Glu81, Val116, His160, and Asp175 appear in the binding cavity, confirming 
the reasonability of docking protocol. For this class of compounds, the docking results in the absence 
of the crystallized waters are poorer than those in the presence of crystallized waters. This is probably 
that crystallized waters are crucial for mediating the interactions between ligand and the protein. 
Compound  38  was  selected  as  a  reference  to  analyze  the  binding  mode  of  docking  shown  in  
Figure 5. Compound 38 locates at a cavity consisting of Leu45, Gly46, Arg47, Val53, Val66, Lys68, 
Ile95, Phe113, Glu114, His115, Val116, Asn118, His160, Met163, Ile174, Asp175, and Trp176. The 
ligand is anchored in the binding site mainly via three H-bonds and two water-mediated contacts with 
the protein. The carboxyl group at position-2 of ring C forms an H-bond with side chain of Lys68  
(–O···HN, 1.9 Å) and the backbone of Asp175 (–O···NH, 1.9 Å), and the nitrogen atom at position-12 
of ring A forms an H-bond with the backbone of Val116 (–N···NH, 1.7 Å). The hydroxyl group at 
position-2 forms two H-bonds with water1 (W1), which itself forms two H-bonds to the backbone  
–NH– of Trp176 and side chain Glu81, respectively. Carbonyl group forms an H-bond with –OH of 
Asp175 through water2 (W2). These results are consistent with the CoMFA and CoMSIA electrostatic 
blue contour at position-2 of ring C which suggests that electropositive substituents in this area can 
increase the activity, and the red contour at position-12 of ring A which indicates that electronegative 
substituents in this area can increase the activity. Furthermore, no amino acid residues appear upon the 
plane of the benzene ring (ring D), indicating that bulky substituents in this position are favored for 
inhibitory  activity.  This  is  also  evidenced  by  the  presence  of  a  sterically  favorable  green  contour 
around this area as seen by the CoMFA and CoMSIA models. While the area above or below ring D is 
occupied by residues of Leu45, Gly46 and His160, suggesting that the substituents bearing side chains 
in this position will conflict with these residues and decrease the inhibitor activity. Therefore, the ring D 
substituent of compound 38 that fits snugly into this hydrophobic cleft would be preferential. 
3.4. Comparison with Binding Modes of 3,8-Dibromo-7-hydroxy-4-methylchromen-2-one (DBC)  
The binding modes of this type of inhibitors were compared with those of DBC on purpose to 
explore their similarities and differences and to get a better understanding of the variations in their 
biological  activities.  DBC  is  the  derivative  of  coumarin  which  belongs  to  natural  benzopyrone 
derivatives. Since benzopyrones widely exist in vegetables, fruit, seeds, nuts, coffee, tea and wine [30], 
it  is  not  difficult  to  see  why  extensive  study  on  their  pharmacological  and  therapeutic  properties  
has  been  underway  over  many  years  [30,31].  Especially,  coumarin  is  a  natural  substance  that  
has  shown  antitumor  activity  in  vivo,  with  the  effect  believed  to  be  due  to  its  metabolites  (e.g.,  
7-hydroxycoumarin) [31]. 
Based  on  the  docking  study,  we  found  that  H-bond  and  water-mediated  interactions  are  both 
important between the CX-4945 inhibitors and the CK2α receptor. For CX-4945 (shown in Figure 5A), 
three direct H-bonds are formed between compound 38 and residues Lys68, Val116 and Asp175. Water 
molecule  (W1)  mediated  interactions  are  formed  between  compound  38  and  residues  Glu81  and 
Trp176. As regards DBC (shown in Figure 5B), it locates at a hydrophobic cavity consisting of the side 
chains  of  Leu45,  Gly46,  Val53,  Lys68,  Ile66,  Phe113,  Glu114,  Val116,  Met163,  Ile174,  Asp175, Int. J. Mol. Sci. 2011, 12 
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Trp176 and Gly177. DBC hydroxyl group forms a direct H-bond with residues Lys68 (–O···HN, 1.8 Å) 
and  Asp175  (–O···HN,  2.5  Å),  respectively.  Furthermore,  the  hydroxyl  group  of  DBC  establishes 
another H-bond with Trp176 backbone via a water molecule (W1), which further confirms that this 
structure is crucial to the DBC inhibitory activities. 
By comparison, we obtained the following conclusions: (1) Note that the DBC is always co-planar, 
but in the CX-4945 case the inhibitor is displaced laterally so that it overlaps different sections of the 
hydrophobic cavity, and in the latter it enters the cavity deeper than the DBC, reaching the hinge 
region, where it establishes more bonds with the receptor; (2) Lys68 and Asp175 are both involved in 
the binding modes, indicating that both of them are important for the interaction between these two 
series of inhibitors and the CK2α protein; (3) Both inhibitors form more than two H-bonds with the 
CK2α,  indicating  that  they  exhibit  potent  inhibitory  activity;  (4)  Besides  the  direct  H-bond,  the 
interaction mediated by water is also vital for the recognition process of both classes of inhibitors. 
Particularly, water molecule that mediates an H-bond between the OH group of inhibitors and the 
Trp176 backbone of CK2α may be conserved. 
Figure 5. Plot of the CK2α structures of the binding site with ligand. (A) The binding 
modes between CX-4945 and CK2α (PDB code: 3NGA). (B) The binding modes between 
DBC and CK2α (PDB code: 2QC6). H-bonds are denoted as dotted black lines. 
 
3.5. MD Simulations Analysis 
To investigate the positional and conformational changes of inhibitors relative to the binding site, a 
5 ns MD simulation was performed based on the crystal structure of CK2α in complex with CX-4945 
(PDB  code:3NGA).  Initially,  to  determine  the  conformational  stability  of  the  CK2α  structure,  the 
RMSD over the lifetime with respect to its starting structure, is examined. The RMSD of all backbone 
atoms as a function of time is depicted in Figure 6(A). After 1.5 ns, the RMSD of the complex reaches 
about 2 Å and retains this value throughout the simulation, indicating that the overall structure of the 
CK2α has reached a stable conformation in time during the simulations. 
For CK2α, CX-4945 is captured in the ATP binding site sandwiched between the C- and N-terminal 
lobes (Figure 7(A)). We found that the condensed planar structure of CX-4945 comprising three flat Int. J. Mol. Sci. 2011, 12 
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rings A, B and C is remarkably stable, displaying backbone RMSF values around 0.6 Å. Whereas the 
side chain (ring D) shows pronounced flexibility with RMSF 2.0 Å. In the CK2α binding cleft, the 
condensed planar structure of CX-4945 binds to the CK2α through the van der Waals contacts and 
hydrophobic interactions with a hydrophobic surface of the CK2α binding cleft formed by residues 
Leu45,  Gly46,  Val53,  Val66,  Ile95,  Phe113,  Met163,  Ile174,  Asp175  and  Trp176  (Figure  8(A)). 
Simultaneously, three direct (between the carboxyl group of ring C and Lys68, between the carboxyl 
group  of  ring  C  and  Asp175,  and  between  the  nitrogen  of  ring  A  and  Val116)  and  W1-mediated  
H-bonds observed from the crystal structure keep stability during the whole simulation (Figure 8(A), 
bottom left and top right), while the W2-mediated H-bond is not conserved in the simulation. These 
interactions including W1-mediated H-bonds enable the CK2α to grasp the ligand tightly.  
At the “mouth” of the CK2α binding cleft where side-chain ring D lies (Figure 8(B)), Gly-rich loop 
backbone (residues 46–51 in CK2α) as the upper lip shows a significant flexibility, which moves ‘‘up’’ 
and is shifted away from the lower lip His160. Meanwhile, the imidazolyl of His160 flips downward, 
thus opening the mouth of the cleft. This enlarged space of the mouth enables ring D to rotate freely to 
explore an optimum pose. This observation highlights the flexibility of the Gly-rich loop and His160, 
which is able to adjust them to the type of ligand present in the cavity. 
Figure  6.  (A)  Time  evolution  of  the  root-mean-square  deviation  (RMSD)  of  CK2α 
measured from the corresponding initial structure. (B) View of superimposed backbone 
atoms of the average structure of the molecular dynamics (MD) simulation (magenta) and 
the starting structure (blue) for CK2α. CX-4945 is shown as ball and stick in magenta for the 
average structure and in blue for initial complex, respectively. 
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Figure 7. (A) Overall structure of the CK2α in complex with CX-4945. The N-terminal 
lobe, which is rich in β-strands and ends at Asn118, is implicated in nucleotide binding. 
The  C-terminal  lobe  is  mainly  α-helical  and  serves  as  a  docking  site  for  substrates.  
CX-4945 binds to the ATP-binding site near the hinge region, which unites both lobes. 
(B) The binding mode between CX-4945 and CK2α. CX-4945 binds to CK2α directly or 
through the water molecules W1 and W2. H-bonds are shown as dotted green lines; Active 
site amino acid residues are represented as sticks; the inhibitor is denoted as stick and 
ball model. 
 
Figure 8. (A) Plot of the MD-simulated structure of the binding site with CX-4945. H-bonds 
are shown as dotted black lines, active site amino acid residues are represented as sticks, 
the inhibitor is shown as stick and ball model, W1 is represented as Vdw, respectively. 
Three direct (D1, D2 and D3) and W1-mediated (D4, D5 and D6) H-bonds keep stability 
during the whole simulation (bottom left), the direct H-bond between the nitrogen of ring A 
and Val116 observed from the crystal structure is also stable in the simulation (top right). 
(B) Superposition of the initial and final snapshots of the CK2α simulation. For clarity, 
only the Gly-rich loop is colored in gray (initial) and red (final). Residue His160 in final 
structure is shown in red stick presentation, while in initial structure is shown in stick 
presentations: cyan for carbon, white for hydrogen, red for oxygen, and blue for nitrogen 
atoms, respectively. As indicated by the red arrows, the Gly-rich loop moves upward while 
His160 flips downward, thus opening the mouth of the cleft. 
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4. Conclusion 
In this study, the ligand-based and receptor-based 3D-QSAR studies using CoMFA and CoMSIA 
approaches have been performed on CX-4945 derivatives as CK2 inhibitors. From the resultant model, 
the established ligand-based 3D-QSAR models show good correlative and predictive ability in terms 
of higher Q
2, Rncv
2, and Rpred
2 values. The resulting contour maps produced by the best CoMFA and 
CoMSIA models provide useful information about the intermolecular interactions of inhibitors with 
the surrounding environment. The results are in good correlation with the specific interactions between 
the  inhibitors  and  the  binding  pocket  of  human  CK2α  identified  in  the  docking  analysis.  MD 
simulation results of CK2α in complex with CX-4945 reveal that CX-4945 forms several direct or 
water-bridged H-bonds with the participation of W1, Leu45, Lys68, Glu81, Val116 and Trp176. These 
hydrogen bonds allow CX-4945 to bind to CK2α strongly and selectively. All these results will be 
extremely  beneficial  for  guiding  future  structural  modifications  and  developing  novel  and  potent 
CK2 inhibitors. 
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